Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease
On Mar. 31, 2026, Biogen and Apellis Pharmaceuticals announced the companies have entered into a definitive agreement under…
-
-
Biotechnology | Disease | FDA | Therapeutics
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
On Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of…
-
Artificial Intelligence | Biotechnology | Diagnostics | Infectious Disease | Medical Device | Neurology | Pharmaceutical | Therapeutics
China biotech deals hit record as innovative drugs draw interest of multinationals
On Mar. 29, 2026, The South China Morning Post reported the cross-border outlicensing activities of Chinese biotech firms…
-
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
On Mar. 29, 2026, generative-AI drug developer Insilico Medicine announced that it has agreed to a global licensing…
-
Biotechnology | Clinical Research | Diagnostics | Environmental | Infectious Disease | NIH | Non-Profit Research | Rare Disease | Therapeutics | Vaccine
NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists
On Mar. 27, 2026, a STAT survey conducted of nearly 1,000 National Institutes of Health (NIH) -supported scientists,…
-
Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation
On Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE…
-
Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body
On Mar. 27, 2026, A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step…
-
Novartis to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline for $3 Billion
On Mar. 20, 2026, Novartis announced an agreement with Synnovation Therapeutics, to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor,…
-
Biotechnology | Disease | FDA | Therapeutics
FDA approves new higher-dose version of Wegovy shots
On Mar. 19, 2026, The U.S. Food and Drug Administration approved a 7.2-milligram dose of Danish drugmaker Novo…
-
Agriculture | Artificial Intelligence | Biotechnology | Diagnostics | Environmental | FDA | Genomics | Imaging | Infectious Disease | Medical Device | Medicine | Nanotechnology | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine | Veterinary | Women's Health
National survey of NIH-funded researchers shows precarious state of U.S. science — ‘This is like the Titanic’
On Mar. 19, 2026, a nationwide STAT survey of federally funded researchers reveals that, a year after Donald…
-
Biotechnology | Cardiology | Diagnostics | FDA | Neurology | NIH | Rare Disease | Therapeutics | Women's Health
NIH invests $150 million in human-based research to reduce use of animal models
On Mar. 18, 2026, the National Institutes of Health (NIH) announced more than $150 million to develop and…
-
New Genetic Risk Score Better Predicts Diabetes, Obesity and Downstream Complications
On Mar. 16, 2026, investigators from Mass General Brigham announce they have built metabolic polygenic risk scores (PRS) for predicting…
-
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
On Mar. 13, 2026, ImmunityBio announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a…
-
Biotechnology | Diagnostics | Medical Device | Medicine | Neurology | Non-Profit Research | Oncology | Pharmaceutical | Radiology | Therapeutics
Mass General Brigham Receives Transformative $50 Million Gift to Shape Future of Cancer Research
On Mar. 12, 2026, Mass General Brigham (MGB) announced it has received a $50 million gift that will…
-
Researchers Develop New Way to Safely Insert Gene-Sized DNA Into the Genome
On Mar. 11, 2026, taking a step towards developing genetic therapies at scale, researchers from Mass General Brigham…
-
New Study Exposes Hidden Alzheimer’s “Hot Spots” in Rural Maryland and What They Reveal About America’s Growing Healthcare Divide
On Mar. 8, 2026, a new statewide spatial analysis of Alzheimer’s disease and related dementias (ADRD) has uncovered…
-
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for Treatment of Adults with Psoriatic Arthritis
On Mar. 6, 2026, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved…
-
Sumitomo Receives Approval for world’s first iPS cell‑derived regenerative medicine in Japan
On Mar. 6, 2026, Sumitomo Pharma announce it has obtained conditional and time‑limited approval in Japan for the…
-
China approves Pfizer GLP-1 drug for weight loss
On Mar. 5, 2026, China has approved Pfizer’s GLP-1 treatment Xianweiying for long-term weight management in overweight or…
-
Study finds First-ever in-utero stem cell therapy for fetal spina bifida repair is safe
On Feb. 26, 2026, A University of California Davis Health research team has safely performed the world’s first spina…
-
Novartis settles with Henrietta Lacks’ estate over use of her ‘stolen’ cells to advance medicine
On Feb. 26, 2026, Novartis announced it has settled a lawsuit by the estate of Henrietta Lacks that…
-
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
On Feb. 23, 2026, Gilead Sciences announced it will buy cancer therapy partner Arcellx for an implied equity…
-
Second $75 million gift from Phil and Penny Knight expands possibilities in care
On Feb. 19, 2026, Phil and Penny Knight announced they have given a second transformational gift of $75 million…
-
Chemistry-Powered “Breathing” Membrane Opens and Closes Tiny Pores on Its Own
On Feb. 18, 2026, researchers at SANKEN, University of Osaka announced using a nanoreactor to produce pores that…
-
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
On Feb. 18, 2026, Johnson & Johnson announced announced a more than $1 billion investment in a next…
-
Scientists develop first-of-its-kind antibody to block Epstein Barr virus
On Feb. 17, 2026, Fred Hutch Cancer Center scientists announced reaching a crucial milestone in blocking Epstein Barr…
-
Artificial Intelligence | Biotechnology | Genomics | Materials | Medical Device | Nanotechnology | Non-Profit Research | Pharmaceutical | Quantum | Therapeutics | U.S. Congress
PNNL Powers Biotechnology, Grid Operations, Nuclear Science Through Genesis AI for Science Mission
On Feb. 17, 2026, the Department of Energy’s (DOE) Pacific Northwest National Laboratory (PNNL) announces it has joined…
-
Lilly to acquire Orna Therapeutics to advance cell therapies for $2.4 billion in cash
On Feb. 9, 2026, Eli Lilly and Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in…
-
Genentech’s Fenebrutinib First Investigational Medicine in Over a Decade That Reduces Disability Progression in Multiple Sclerosis
On Feb. 7, 2026, Genentech, a member of the Roche Group, announced late-breaking data from the Phase III…
-
CDC study highlights growing threat of invasive E coli
On Feb. 6, 2026, A study by federal and state health researchers indicates invasive Escherichia coli infections are…
